Core Insights - Natera reported Q3 CY2025 results that exceeded Wall Street's revenue expectations, with a year-on-year sales increase of 34.7% to $592.2 million [1][9] - The company's full-year revenue guidance was raised to $2.22 billion, which is 6.1% above analysts' estimates [1] - Natera's GAAP loss per share was $0.64, which was 74.5% below analysts' consensus estimates [1] Company Overview - Natera, founded in 2003 and rebranded in 2012, specializes in genetic tests for prenatal screening, cancer detection, and organ transplant monitoring using proprietary cell-free DNA technology [4] Revenue Growth - Natera achieved a compounded annual growth rate of 42.4% in sales over the last five years, outperforming the average healthcare company [5] - The company's annualized revenue growth over the last two years was 46.3%, indicating strong and accelerating demand [6] Financial Performance - Q3 revenue was $592.2 million, surpassing analyst estimates of $514.4 million by 15.1% [7] - The company raised its full-year revenue guidance from $2.06 billion to $2.22 billion, reflecting a 7.8% increase [7] - Operating margin was reported at -16.5%, a decline from -8.9% in the same quarter last year [7] Sales Volume and Market Dynamics - Sales volumes increased by 21.4% year-on-year, compared to 28% in the same quarter last year [7] - The number of tests processed reached 893,600 in the latest quarter, with a two-year average growth of 20.8% year-on-year, indicating that revenue growth was supported by price increases [8]